Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000037303
Ethics application status
Approved
Date submitted
23/12/2016
Date registered
10/01/2017
Date last updated
12/07/2023
Date data sharing statement initially provided
23/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
A study of EnGeneIC Dream Vectors (EDV's) packaged with the chemotherapy PNU-159682, given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-60mer, in participants with advanced cancer who have no curative treatment options. .
Scientific title
A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (EGFR(V)-EDV-PNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDV-60mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options
Secondary ID [1] 290795 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Designer EDV / ENG8
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 301438 0
Advanced Solid Tumours 301439 0
Condition category
Condition code
Cancer 301159 301159 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is an open-label feasibility study of Epidermal Growth Factor Receptor (EGFR)(V)-EDVs containing PNU-159682 administered via intravenous (IV) infusion in combination with EDVs containing an immunomodulatory adjuvant (EDV-60mer), in subjects with advanced solid tumours who have no curative treatment options.

EGFR(V)-EDV-PNU and EDV-60mer will be mixed together and administered intravenously in cycles consisting of weekly infusions for 7 weeks (7 doses), followed by a treatment free week in which tumours are assessed radiologically (week 8).

Two dose levels will be explored according to standard 3+3 dose escalation guidelines. The first dose level of EGFR(V)-EDV-PNU will be 2.5 x 10^9. The starting dose of EDV-60mer will be 5 x 10^8,

EGFR(V)-EDV-PNU will be gradually escalated from dose 1 of the first treatment cycle to reach the required maximum dose level. Intra-cycle dose escalation is intended to build treatment toleration.

The second dose level will be 5 x 10^9 of EGFR(V)-EDV-PNU, the concurrent dose of EDV-60mer will be 2 x 10^9,

On determination of the recommended phase two dose (RP2D), additional participants will be enrolled at this dose level up to a total of 20 for the whole study. If both dose levels are deemed safe, then the highest dose level administered will be the RP2D (i.e. Dose Level 2 with 5 x 109 EGFR(V)-EDV-PNU and 2 x 109 EDV-60mer).

A participant may continue EGFR(V)-EDV-PNU with concurrent adjuvant EDV-60mer treatment as long as their disease is responding or remains stable, the participant does not experience any unacceptable toxicity or withdraws consent or at the discretion of the Investigator withdrawal is felt to be in the best interests of the participant.
Intervention code [1] 296707 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 300570 0
Assess the safety and tolerability of EGFR(V)-EDV-PNU (with adjuvant EDV-60mer) in subjects with advanced solid tumours.
Timepoint [1] 300570 0
Safety assessment will involve recording the incidence of Adverse Events (AEs) and clinically significant changes in vital signs and clinical laboratory tests. AE's and vital signs will be assessed pre-dose infusion and then at 1, 2 and 3 hours post each dose infusion and at 14 day withdrawal visit and 30-35 days post final dose.

A designated Safety Review Committee will assess if any reported adverse event including Serious Adverse Events (SAE's) and Suspected Unexpected Serious Adverse Reactions (SUSAR's) are attributable to the study treatment and fulfill the protocol defined criteria of a Dose Limiting Toxicity (DLT).

Participants will be assessed for DLTs within the first 28 days of treatment. and will include up to the first 6 subjects enrolled at each dose level. In the case of missed doses, the DLT evaluable period will be extended by 7 days for each missed dose so that a DLT evaluable subject is defined as having received 4 doses and been evaluated for 7 days following each dose.
Primary outcome [2] 300572 0
Assess anti-tumour response in subjects with advanced solid tumours who have exhausted all curative treatment options when administered EGFR(V)-EDV-PNU (with adjuvant EDV-60mer).
Timepoint [2] 300572 0
Evidence of anti-tumour activity will be assessed radiologically, and response graded according to iRECIST criteria. The overall response for each subject will be recorded at Week 8 of every cycle of treatment for the duration of treatment.. Results for best overall response (i-Complete Response, i-Partial Response, i-Stable Disease, i-Unconfirmed Progressive Disease, i-Progressive Disease) will be presented for individual subjects, and for the whole cohort or relevant subsets if applicable using frequency counts and percentages.
Primary outcome [3] 300648 0
Overall survival (OS) in subjects with advanced solid tumours who have exhausted all curative treatment options when administered EGFR(V)-EDV-PNU (with adjuvant EDV-60mer).
Timepoint [3] 300648 0
Survival will be presented as months following administration of Dose 1 for individual subjects, and overall or for relevant subsets if applicable (particularly the cohort treated at the RP2D). Survival will continue to be monitored for the duration of the long term follow-up (every 3 months from the safety follow-up visit, for a period of 12 months, and then for the extent of subject survival). Kaplan Meier curves will be utilised to determine percentage and median survival. There is no control arm for this study. Survival will be compared to historic survival data for individual tumour types.
Secondary outcome [1] 330339 0
Assess immune response in subjects administered EGFR(V)-EDV-PNU (with adjuvant EDV-60mer).
Timepoint [1] 330339 0
Blood samples will be collected from all subjects for culture of Peripheral Blood Mononuclear Cells (PBMCs) to assess immune response in vitro at screening and then at pre-Dose 7 (last dose) for each cycle.
Secondary outcome [2] 330503 0
Assess cytokine responses in subjects administered EGFR(V)-EDV-PNU (with adjuvant EDV-60mer).
Timepoint [2] 330503 0
At Cycle 1, collection of blood samples (pre-dose and 3 hours post-dose) will be taken for cytokine response analyses at each dose ,For all subsequent cycles the blood samples will be performed at dose 1 (pre and post dose) only.

Eligibility
Key inclusion criteria
1. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
2. Life expectancy greater than 3 months
3. Histologically or cytologically confirmed advanced solid tumour that is metastatic or unresectable and for which standard curative or palliative measures are not available or are no longer effective.
4. Measurable disease per iRECIST criteria.
5. Able to undergo CT or MRI (+/- PET) evaluation as applicable to tumour type.
6. Available archived primary or metastatic neoplastic tumour tissue available for EGFR expression staining, if not already performed as standard of care.
6.. Adequate cardiac function with LVEF greater or equal to 50% at baseline.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Significant pericardial effusions, pleural effusions or ascites.
2. Concurrent unstable diabetes mellitus or other contraindications for the use of dexamethasone.
3. Uncontrolled concurrent cardiac disease including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
4. Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis.
5. History of uncontrolled arterial or venous thrombosis. Subjects with a history of arterial or venous thrombosis are eligible if the subject is controlled on low dose molecular weight heparins or low dose aspirin.
6. Uncontrolled brain metastases. Subjects with a history of brain metastases are eligible if the subject is stable and off corticosteroids for at least 2 weeks prior to treatment in the study. PAtients who have undergone glucocorticoid tapering but who have not tolerated complete withdrawal and still require a nominal maintenance dose, will be reviewed on a case by case basis.
7. Active or uncontrolled severe infection.
8. Previous or current primary malignancies at other sites within last 2 years, except:
- In situ carcinoma of the cervix
- Adequately treated basal cell or squamous cell carcinoma of the skin.
9. Received therapies or procedures within 28 days prior to Cycle 1, Dose 1 (or has not recovered from the toxic effects of such therapy) including:
- Therapy with an EGFR inhibitor e.g. cetuximab or erlotinib
- Anti-angiogenic therapy e.g. Bevacizumab (Avastin)
- Immunotherapeutic agents, vaccines, or monoclonal antibody therapy
- Alkylating agents
- Chemotherapy
- Radiotherapy with the exception of palliative radiotherapy
- Other investigational therapy.
- Any major surgery.
10. Prior exposure to PNU.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Due to the small number of subjects to be enrolled, and the range of tumour types for possible evaluation, findings will be presented in a descriptive manner with no formal statistical comparisons performed.

Data will be presented for individual subjects. Where feasible (e.g. for subjects with the same tumour type, or for variables relevant to general EDV administration), continuous data will be summarised by the following descriptive statistics: n (number of observations), mean, standard deviation, median, minimum, maximum. Categorical data will be summarised by frequencies and percentages.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
19/05/2017
Actual
19/05/2017
Date of last participant enrolment
Anticipated
30/09/2019
Actual
22/01/2020
Date of last data collection
Anticipated
31/12/2023
Actual
Sample size
Target
20
Accrual to date
Final
15
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 10229 0
Peninsula Oncology Centre - Frankston
Recruitment hospital [2] 10230 0
Peninsula Oncology Centre - Frankston
Recruitment postcode(s) [1] 21893 0
3199 - Frankston
Recruitment postcode(s) [2] 21894 0
3199 - Frankston

Funding & Sponsors
Funding source category [1] 295222 0
Commercial sector/Industry
Name [1] 295222 0
EnGeneIC Pty Limited
Country [1] 295222 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
EnGeneIC Pty Limited
Address
Building 2/25 Sirius Rd.
Lane Cove West
NSW 2066
Country
Australia
Secondary sponsor category [1] 294050 0
None
Name [1] 294050 0
Address [1] 294050 0
Country [1] 294050 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 296566 0
Monash Health Human Research Ethics Committee
Ethics committee address [1] 296566 0
Ethics committee country [1] 296566 0
Australia
Date submitted for ethics approval [1] 296566 0
01/12/2016
Approval date [1] 296566 0
30/03/2017
Ethics approval number [1] 296566 0
HREC/16/MonH/407
Ethics committee name [2] 299766 0
Bellberry Limited Human Research Ethics Committee
Ethics committee address [2] 299766 0
Ethics committee country [2] 299766 0
Australia
Date submitted for ethics approval [2] 299766 0
15/11/2017
Approval date [2] 299766 0
02/01/2018
Ethics approval number [2] 299766 0
2017-11-845
Ethics committee name [3] 299767 0
Bellberry Limited Human Research Ethics Committee
Ethics committee address [3] 299767 0
Ethics committee country [3] 299767 0
Australia
Date submitted for ethics approval [3] 299767 0
15/11/2017
Approval date [3] 299767 0
02/01/2018
Ethics approval number [3] 299767 0
2017-11-845

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 71298 0
A/Prof Vinod Ganju
Address 71298 0
Peninsula and Southeast Oncology Suite 7, Level 3 North Building, Frankston Private Hospital, 5 Susono Way, Frankston VIC 3199
Country 71298 0
Australia
Phone 71298 0
+61-3-9781-5244
Fax 71298 0
Email 71298 0
[email protected]
Contact person for public queries
Name 71299 0
Albert Goikhman
Address 71299 0
Peninsula and Southeast Oncology Suite 7, Level 3 North Building, Frankston Private Hospital, 5 Susono Way, Frankston VIC 3199
Country 71299 0
Australia
Phone 71299 0
+61-3-8572-2429
Fax 71299 0
Email 71299 0
[email protected]
Contact person for scientific queries
Name 71300 0
Jennifer MacDiarmid
Address 71300 0
EnGeneIC Pty Limited
Building 2/25 Sirius Rd.
Lane Cove West,
NSW 2066
Country 71300 0
Australia
Phone 71300 0
+61-2-9420-5833
Fax 71300 0
Email 71300 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseCyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells.2020https://dx.doi.org/10.1016/j.ccell.2020.02.001
N.B. These documents automatically identified may not have been verified by the study sponsor.